首页> 外文会议>IEEE International Symposium on Biomedical Imaging >A method for quantification of calponin expression in myoepithelial cells in immunohistochemical images of ductal carcinoma in situ
【24h】

A method for quantification of calponin expression in myoepithelial cells in immunohistochemical images of ductal carcinoma in situ

机译:导管癌原位免疫组化图像中肌钙蛋白表达的定量方法

获取原文

摘要

Ductal carcinoma in situ (DCIS) is breast cancer confined within mammary ducts, surrounded by an intact myoepithelial cell layer that prevents local invasion. A DCIS diagnosis confers increased lifetime risk of developing invasive breast cancer (IBC) and results in surgical excision with radiation, and possibly endocrine- or chemo-therapy. DCIS is known to be over treated, with associated co-morbidities. Biomarkers are needed that delineate patients at low risk of DCIS progression from patients requiring more aggressive treatment. Investigating the role of myoepithelial cell differentiation in barrier function is anticipated to provide insight into DCIS progression and delineate between low and high risk lesions. Here, we develop a high throughput technique to assess loss of myoepithelial differentiation markers. This method facilitates automated analysis of a clinically relevant histopathologic feature, as demonstrated by a high correlation with pathologist annotation (r = 0.959), and further, contributes analytical foundations to a multiplexed immunohistochemistry (IHC) approach.
机译:乳腺导管原位癌(DCIS)是局限于乳腺导管内的乳腺癌,周围是完整的肌上皮细胞层,可防止局部浸润。 DCIS诊断赋予终生罹患浸润性乳腺癌(IBC)的风险,并导致手术切除并伴有放射线,可能还会进行内分泌或化学疗法。已知DCIS被过度治疗,并伴有合并症。需要生物标志物来区分低DCIS进展风险的患者和需要更积极治疗的患者。预期调查肌上皮细胞分化在屏障功能中的作用可提供对DCIS进展的了解,并在低风险和高风险病变之间划定界限。在这里,我们开发了一种高通量技术来评估肌上皮分化标记的损失。这种方法有助于对临床相关的组织病理学特征进行自动分析,这与病理学家的注释具有高度相关性(r = 0.959),并且进一步为多重免疫组织化学(IHC)方法提供了分析基础。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号